Nasdaq

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of ...
Nasdaq

Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that ...
FierceBiotech

Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations

Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Confernces CHARLOTTESVILLE, Va., Feb. 6 /PRNewswire/ -- Diffusion ...
FierceBiotech

New Patents Issued to Diffusion Pharmaceuticals

Diffusion Pharmaceuticals LLCMedia:David G. Kalergis, MBA/JDCEO434-220-0718orGBM Study Information:Kim Whitten, Pharm.D,Vice President, Drug Development434-220-0718 Diffusion Pharmaceuticals LLC, a ...
Seeking Alpha

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding ...

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process Diffusion received bids from more than 15 companies ...
Virginia Business

Diffusion Pharmaceuticals names CFO

Diffusion Pharmaceuticals Inc. in Charlottesville has promoted William Hornung to chief financial officer. Diffusion is a biotechnology company developing new treatments for life-threatening medical ...
Seeking Alpha

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative ...
equities

Diffusion Pharmaceuticals (DFFN) Launches Phase 3 Trial for Glioblastoma

Glioblastoma is an extremely aggressive central nervous system tumor that forms on astrocytes, the star-shaped cells that form the supportive tissue of the brain. Also known as glioblastoma multiforme ...
Business Wire

Diffusion Pharmaceuticals LLC Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments for major unmet medical needs, today announced that it has closed ...
CNN

Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for ...
FiercePharma

Diffusion Pharmaceuticals LLC Closes on $5 Million Financing; Continues Phase 2 Clinical Trial In Primary Brain Cancer

<0> Media:David G. Kalergis, MBA/JDCEODiffusion Pharmaceuticals LLC2020 Avon Court, # 4Charlottesville, Virginia 22902Tel: (434) 220-0718Email: orGBM Study Information:Kim Whitten, Pharm.D,Vice ...